MoneyThe story, in brief
Imperagen raises £5 million to use quantum physics, AI on enzyme engineering
£5M. Imperagen just closed its seed to merge quantum physics with AI for enzyme design—a playbook that could reshape biotech's compute bottleneck.
The KeyNews take
Why it matters
Biotech is adopting AI + quantum computing to accelerate protein/enzyme design. This signals a new funding thesis: AI as the enabling layer for wet-lab breakthroughs, not just software plays.
The key facts
8 to knowSeed round: £5M ($6.7M)
Lead investor: PXN Ventures
Co-investors: IQ Capital, Northern Gritstone
Focus: Quantum physics + AI for enzyme engineering
Announced: May 21, 2026
£5 million ($6.7M) seed round
Led by PXN Ventures
Announcement date: May 21, 2026
Go to the source
TechCrunch Startupstechcrunch.com
Publisher excerpt: Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone.